Dr. Bowdish joined PIC Therapeutics as its President & CEO in August 2020, bringing more than 20 years of biopharmaceutical business and scientific acumen and leadership to the company.  PIC Therapeutics is a pre-clinical company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the regulation of RNA translation into proteins.

Prior to PIC Therapeutics, Kathy was most recently at Sanofi for a 7-year tenure, where she launched and led Sanofi Sunrise, a venture investment and partnering vehicle to accelerate early stage pioneering science for patient benefit, and later served as Vice President and Head of R&D Strategy.

Prior to her leadership roles at Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies.  Kathy’s positions included President & CSO, Permeon Biologics; President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals, and Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.